Background and Regulatory Significance of Approval

The European Medicines Agency (EMA) granted a Marketing Authorisation for Lenalidomide Mylan (manufacturer: Mylan Pharmaceuticals Limited, now part of Viatris) on December 18, 2020. Registered under the EMA product number EMEA/H/C/005306, this product is a bioequivalent generic of Bristol Myers Squibb (BMS, BMY)'s original drug, Revlimid (lenalidomide, ATC L04AX07). Revlimid, developed by Celgene (acquired by BMS in 2019) and approved by the EMA in 2007, is an immunomodulatory drug (IMiD) that has been a cornerstone of first-line treatment for multiple myeloma for nearly 20 years. This generic approval is significant from a regulatory perspective as it officially marks the beginning of a price competition era for lenalidomide in Europe.

Mechanism of Action and Indications

Lenalidomide is a cereblon (CRBN) E3 ubiquitin ligase modulator (CELMoD) that alters the substrate specificity of the CRL4CRBN complex, selectively degrading IKZF1 (Ikaros), IKZF3 (Aiolos), and CK1α proteins. This results in the simultaneous inhibition of IRF4 expression, activation of T cells and NK cells, and inhibition of tumor angiogenesis, making it a multi-faceted drug. The EMA-approved indications include: ① maintenance therapy after autologous hematopoietic stem cell transplantation (ASCT), ② first-line treatment in transplant-ineligible newly diagnosed patients in combination with dexamethasone, bortezomib, and melphalan, ③ treatment of relapsed/refractory multiple myeloma in combination with dexamethasone, and ④ treatment of follicular lymphoma with prior rituximab therapy (grades 1-3a). These are a total of four indications.

Market Size and Competitive Landscape

The European market for multiple myeloma treatments is projected to reach USD 9.72 billion in 2024 and grow to USD 14.18 billion by 2030, with a CAGR of 5.76%. The original Revlimid generated global sales of USD 12.8 billion in 2021, ranking it among the top five pharmaceutical products of all time, and continues to generate approximately USD 10 billion in sales in 2024. However, daratumumab (Darzalex, Janssen/J&J, USD 11-12 billion in 2024), carfilzomib (Kyprolis, Amgen), pomalidomide (Imnovid/Pomalyst, BMS), and CAR-T therapies such as ciltacabtagene autoleucel (Carvykti) and idecabtagene vicleucel (Abecma), as well as bispecific antibodies (Tecvayli, Elrexfio), are structurally eroding the market share of lenalidomide-based therapies.

Generic Strategy and Accessibility Impact

Viatris (formerly Mylan, VTRS) has secured regulatory approval from the EMA, establishing a legal basis for supplying affordable alternatives in the European market for high-priced hematological cancer treatments. While the annual cost of the original Revlimid is USD 235,920, the generic version is priced at USD 208,188, representing a reduction of approximately 12%. However, reimbursement decisions by national healthcare systems are made independently of EMA approval, making the reimbursement decisions of HTA (Health Technology Assessment) bodies such as NICE (UK), HAS (France), and G-BA (Germany) critical determinants of actual patient access.

Safety Profile and Regulatory Requirements

Lenalidomide is associated with severe hematological toxicities (neutropenia and thrombocytopenia), thromboembolic events (VTE), and potent teratogenicity, as demonstrated in animal studies. Therefore, a strict Pregnancy Prevention Programme (PPP) and patient/physician education materials are required by the EMA. The revised 14th edition of the EPAR, updated on June 12, 2026, is valid, demonstrating that the EMA continuously incorporates post-marketing data. The same safety management system must be maintained by the generic supplier, making Viatris's pharmacovigilance capabilities a prerequisite for its continued operations in Europe.